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344 pp. $35.00The author of the Genealogy of a Gene,
Myles W. Jackson, uses the gene CCR5
as a window framing a vista of bio-
capitalism. With many compartmental-
ized panes, this window looks at different
edges of its scene as the author retells
the scientific and pharmaceutical history
of CCR5, discusses the world of intellec-
tual property, and ends with thought-
provoking final chapters that show
where the author’s heart lies as he invites
his audience to reconsider some as-
sumptions and unite with historians and
anthropologists before diving into the
world of ‘‘racial’’ and ‘‘ethnic’’ descrip-
tions to distinguish populations. Each of
the subjects is given scholarly treatment
with an exceptional number of notes to
chapters and references.
The late Jonathan Mann once stated
that the earliest years of HIV/AIDS
research saw the fastest advances in
medical history from the onset of a new
disease. In 4 years, U.S. clinicians first
described the disease, CDC defined the
risk factors, the virus was linked to AIDS,
the blood test was developed, the target
cells identified, the genome of HIV
sequenced, most genes and proteins
determined, early mechanisms of patho-
genesis elucidated, HIV variation discov-
ered, the beginning of systemic therapy
for a viral disease initiated, and reagents
made available worldwide. Almost rivaling
those beginning years of HIV/AIDS
research, another period (1995–1996) in-
cludes the development of combination
anti-HIV drugs that changed a horror story
to a treatable chronic disease and another
extraordinary advance which gave rise to
this book: finding the HIV co-receptor,
which on first thought would not appear
to be such a milestone as to provide
Jackson a book opportunity.
The story begins with evidence that
more than CD4 was needed for HIV to
enter cells, followed by the finding that b
chemokines, known ligands for CCR5,
were powerful blockers of HIV infection.It was quickly shown that CCR5 was
indeed a critical co-receptor for HIV.
Soon the famous CCR5-D32 mutant re-
sulting in a disabled protein unable even
to reach the cell membrane was discov-
ered. The consequence is a slowing of
progression to AIDS in an already infected
person heterogeneous for the mutant
gene, and in some cases of homogenous
CCR5-D32 mutations, complete protec-
tion against infection from HIV. When a
strikingly greater prevalence was found
in northern Europeans, race and ethnicity
became a subject of interest. So began
a search for the origin of the presumed
selective pressure that gave rise to
CCR5-D32 and a number of false hypo-
theses beginning with the Black Death
plague of the 14th century and the
assumption that some advantage came
by way of D32. This was presented
with fanfare in general media, but it was
soon discovered that the mutations were
of similar frequency in people who died
of plague versus those who died from
famine. The theory was slowly eliminatedCell 16to be picked up by a small pox hypothe-
sis, though by this time the International
Haplotype Map was showing no evidence
of any selection for CCR5-D32 unless it
was over 1,000 years ago, leading to the
suggestion that the organism responsible
for CCR5-D32 was likely a filovirus
causing hemorrhagic fever, such as
Ebola, and dispersed by Vikings. More
recently, a 2,000 year history has been
more convincingly argued, with the virus
becoming more prevalent in the early
renaissance because of sporadic epi-
demics of these hemorrhagic viruses,
and suggesting the ancient Romans
dispersed it. It is important to note that
these hypotheses are based on very
limited data and rely on history and
mathematical modeling except one—the
recent discovery that CCR5-deficient
mice resist Staphylococcus aureus infec-
tion, providing the first laboratory result
suggestive of a mechanism. The story is
yet unsettled, but it provides Jackson
the first of his several pleas for new coop-
eration between scientists, anthropolo-
gists, and historians.
Companies soon entered the field envi-
sioning therapeutic strategies by discov-
ering molecules that bind to CCR5 and a
diagnostic for CCR5-D32 for determining
(1) if one was less likely to be infected;
(2) if infected, predicting progression at a
slower rate; or (3) for identification of
CCR5-D32 people whose bone marrow
could be used for transplanting HIV-resis-
tant cells to an HIV infected person as
was carried out in the one suspected
HIV cure—the so-called Berlin patient,
although this a dangerous and generally
impractical approach. Thus began an
intensification of biotech and pharmaceu-
tical competition over intellectual property
and patent validity and the entry of ‘‘race’’
and ‘‘ethnicity’’ into the story. Pfizer uti-
lized a modern approach of screening
by a receptor binding assay to identify
Maraviroc as its lead entry blocker. From
the pioneering studies that led to AZT
and subsequent development of a host
of other RT inhibitors by a number of
companies—culminating in the so-called
cocktail of HIV protease inhibitors and
RT inhibitors. Still more inhibitors were
brought forward, and it is in the latter
part of these developments that Mara-
viroc made its debut. Since so many
drugs are needed because of side effects1, June 18, 2015 ª2015 Elsevier Inc. 1483
and drug resistance, Maraviroc was
introduced because its mode of action
was novel, its tolerance excellent, and
its capacity to reduce HIV high. Yet today
it remains reserved for drug-resistant
patients likely because of its cost,
although India produces the generic
version at a lower price. The question is
raised, but never answered, regarding
how much it cost the industry to develop
this drug. The unsolved problem is what
is a fair price and how can the more
expensive drugs be made available
to all? Clearly this requires government
intervention.
But the position of Jackson’s heart is
never in doubt. Nowhere is this more
evident than the first discussion of gene
patenting—the story of Human Genome
Science (HGS) and its founder, William
Haseltine. HGS succeeded in obtaining a
patent for virtually all uses of chemokine
receptors discovered in the future, though
having only a partial gene sequence
that had some homology to known se-
quences of chemokine receptors, but no
actual identity or function, let alone dis-
ease association and medical use of
the approved sequence. Shortly after the
HGS patent, work from academia in
search of the HIV co-receptor made the
essential discoveries related to CCR5,
including its practical uses. I find the
HGS patent on CCR5 analogous to a
man who finds and stores a piece of
onyx. Someone else soon discovers the
same anddemonstrates that it has several
uses by its sharpness that is unrecognized
by the ‘‘picker,’’ who is able to control all
future use of onyx. Whereas it is possible
to understand complexities facing the
U.S. patent office, it is impossible to agree1484 Cell 161, June 18, 2015 ª2015 Elsevierwith their original decision. Jackson then
presents his case against the wide use
of patents especially by scientists in
academiabyusinghistory (Germanchem-
istry) and several other enlightening stor-
ies. However, I amnot convinced by Jack-
son in two arguments: his generalization
from discussions with some scientists
who stated that it was competitive recog-
nition of discovery that gave them their
drive and not the desirability of patents,
and second, that because the U.S. gov-
ernment provides substantial research
funding there is little need for academics
to favor relationships with companies
that provide funding. In the former, I find
scientists vary greatly with respect to their
interest in patents as a helpful motivator.
As to the latter,most biomedical scientists
today are keenly aware of the relative
decline in NIH available funding, and I sus-
pect a significant percent favor funding
from pharmaceutical or biotech indus-
tries, especially when the ‘‘price’’ is right,
the relationship not overdone, and all of it
well monitored.
Another view from Jackson’s window
shows the potential for use of genomics
and development of drugs that are
race directed and even challenges us to
define race and our avoidance of other
parameters for genealogy studies instead
of race. He notes that drugs that appear
to work better with certain races some-
times ‘‘save’’ a drug that failed in an
earlier study of the general population.
The approach also appeals to the current
cry for precision medicine and even to
racial communities seeking greater medi-
cal focus on their needs. Jackson points
out that in some instances, these claims
have been based on shady results. ForInc.me, these discussions were eye-openers
and suggest deeper thought is needed
by those of us in biomedical research
when we draw race-related inferences
from genomics or think we are on the right
track when we select drugs for different
races predicated on so-called precision
medicine.
Though not stated as such, the author
has recommendations throughout the
book. They include: (1) The need for
interactions of molecular geneticists with
other field leaders especially historians
andanthropologists; (2) precise definitions
of race and ethnicity prior to their use in
genomic studies; (3) using parameters
other than race in comparative genetic
studies, e.g., geography, climate, popula-
tion histories; (4) a continued debate on
what is patentable; (5) greater consider-
ation of the negative impacts of patents
on science progress and affordability of
available drugs; and (6) a rethinking of the
financial need for academics relying on in-
dustry for financial support.
Jackson’s epilogue closes with his
statement that the book ‘‘has gestured
at the role of history in public policy .
told the tale of historical alternatives’’
with an attempt to ‘‘resurrect the past to
illustrate the paths not taken’’ and the
reason why. He notes, ‘‘Histories that
feature only the victors and that forget
that objects can be exploited by those in
power with sinister results.’’ This is a
poignant ending but the book is more. It
is also an exceptionally well-documented
analysis of the intricacies and dilemmas of
modern biomedical science through the
window of a gene—intimately involved in
the outcome of one of the greatest pan-
demics of modern times.Robert C. Gallo
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